Exousia Bio (LMMY) Liabilities and Shareholders Equity (2022 - 2026)

Exousia Bio (LMMY) has 5 years of Liabilities and Shareholders Equity data on file, last reported at $22.1 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity changed N/A year-over-year to $22.1 million in Q1 2026, while the trailing twelve-month figure through Feb 2026 was $44.1 million (up 54844.67% YoY) and the FY2024 annual result came in at $27453.0, down 25.89% from the prior year.
• Liabilities and Shareholders Equity steadied at $22.1 million in Q1 2026 per LMMY's latest filing, from $22.1 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $22.1 million in Q4 2025, with the low at $24854.0 in Q4 2024.
• Average Liabilities and Shareholders Equity over 5 years is $4.0 million, with a median of $27958.0 recorded in 2024.
• Year-over-year, Liabilities and Shareholders Equity tumbled 31.39% in 2023 and soared 88620.81% in 2025.
• Exousia Bio's Liabilities and Shareholders Equity stood at $53996.0 in 2022, then sank by 50.47% to $26742.0 in 2023, then decreased by 7.06% to $24854.0 in 2024, then soared by 88620.81% to $22.1 million in 2025, then changed by 0.0% to $22.1 million in 2026.
• Business Quant data shows LMMY's Liabilities and Shareholders Equity at $22.1 million in Q1 2026, $22.1 million in Q4 2025, and $24854.0 in Q4 2024.